GLP1R and type 2 diabetes mellitus: The study found that use of GLP-1 RAs was associated with significant reductions in CV and all-cause mortality, and the researchers suggested that GLP-1 RAs should be used as a first-line treatment in patients with T2DM at higher CV risk or as a first-line treatment in patients with metformin resistance (46).